title: [Treatment of a septic patient with acquired haemophilia].
abstract: BACKGROUND
  Acquired haemophilia is a rare bleeding diathesis caused by auto-immune depletion of factor VIII. It is characterised by spontaneous haemorrhagic syndrome, which can be fatal sometimes.
  
  
  METHODS
  A 71 year-old man presents in a dysimmunitary context (rheumatoid arthritis complicates by an acquired haemophilia) a septicemia with a methicillin resistant staphylococcus aureus. At the time of the hospitalization, the patient is febrile (39 degrees C). The activated partial thromboplastin time is very much increased, the level of factor VIII is lowered by 7% and the title of the inhibitor to factor VIII amounts to 140 Bethesda unities. An haematoma of the right root thigh is also noted. In that case, the concomitant presence of septicemia makes difficult the use of immunosuppressive therapy usually recommended to decrease auto-antibody's level. For the management of the septicemia, an adapted antibiotherapy (vancomycin then teicoplanin) is organized to J1. To control haemorrhagic risk, immunoglobulins are prescribed from d12 to d16, without immediate results. Then prednisone is introduced. We observe a very fast decrease of the anticoagulant circulating title with a neat improvement of the clinical state, allowing so to realize a draining puncture of the psoas. This invasive investigation required the use of prothrombinic complex concentrates ((Feiba) in the dose of 80 UI/kg two to three times a day). Biopsy does not show infection source.
  
  
  CONCLUSIONS
  The infection delayed the prescription of immunosuppressive therapy and the surgery. Use of corticoids, following 5 days of intravenous polyvalent immunoglobulin, was the good choice. After 7 weeks of hospitalization the patient has recovered a normal haemostasis results, and a good general state.
authors.affiliation: Service pharmacie, hôpital Purpan, CHU Toulouse, place Baylac, 31059 Toulouse cedex, France.
authors.forename: F
authors.initials: F
authors.lastname: Laporte
authors.forename: P
authors.initials: P
authors.lastname: Cestac
authors.forename: V
authors.initials: V
authors.lastname: Favre
authors.forename: X Seree
authors.initials: XS
authors.lastname: DeRoch
authors.forename: S
authors.initials: S
authors.lastname: Khatibi
authors.forename: E
authors.initials: E
authors.lastname: Bonnet
authors.forename: P
authors.initials: P
authors.lastname: Massip
authors.forename: P
authors.initials: P
authors.lastname: Sie
authors.forename: B
authors.initials: B
authors.lastname: Bellon
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D016470:Bacteremia / Q000150:complications*; D006467:Hemophilia A / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D011241:Prednisone / Q000627:therapeutic use*; D013203:Staphylococcal Infections / Q000150:complications*
chemical_list: D000893:Anti-Inflammatory Agents; D011241:Prednisone